Events | 2019.04.17
Alligator Bioscience AB (publ) Interim Report January-March 2019
STOCKHOLM, April 17, 2019 /PRNewswire/ -- Significant events January-March First patient dosed in Phase I clinical study of ATOR-1015. New preclinical data presented demonstrating strong anti-tumor effects for the 4-1BB antibody ATOR-1017. Alligator Bioscience launched RUBY™, a novel...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]uary-march-2019-300833596.html
